Congrès Mondial de Dermatologie Vétérinaire: la Dermatite Atopique à l'Honneur

Dans son éditorial de la lettre d’info de l’ISAD, le Pr Alain Taïeb fait un tour d’horizon des tendances des publications sur la DA et conclut sur la nécessité de promouvoir la recherche indépendante et la créativité, de trouver un équilibre subtil entre les présentations de recherche académique indépendante et celles de l'industrie lors des réunions. Fervent partisan des échanges avec le monde vétérinaire, il insiste sur les apports d’une approche One Health de la DA. Pour preuve les deux symposiums déjà organisés par l’ISAD :

• Examining Atopic Dermatitis through the One Health concept
• Comparative Therapy: Human vs Canine AD

Côté vétérinaire, nous serions bien en mal de faire un éditorial tirant des leçons de 50 à 80 publications hebdomadaires comme c’est le cas en médecine humaine.

Celles sur la DA canine n’atteignent pas ce nombre… sur une année et encore, en incluant les recensions diverses.

Il est d’ailleurs intéressant de voir à quel point nous sommes capables de publier des recommandations ou des « CAT », alors même que notre littérature est cachectique et de qualité hétérogène, voire majoritairement médiocre.

Les recherches indépendantes sont trop rares et parfois biaisées par la nécessité de publier dans le cadre d’un résidanat

Ne crions pas au loup, les recherches orientées par l’industrie pharmaceutiques portent leurs fruits et permettent d’offrir de nouveaux débouchés thérapeutiques.

Il faut que nous publiions plus d’études cliniques indépendantes, que nous avancions sur des consensus réels dans de nombreux domaines : phénotypes, efficacité thérapeutique, scores de suivi, place de l’allergie, standardisations des démarches diagnostiques…

Nul doute que le 10e congrès de dermatologie vétérinaire nous apportera de très jolies surprises et répondra à cette demande, avec de (très nombreuses) présentations aux titres alléchants :

1. Current insight into the molecular pathogenesis of canine atopic dermatitis
2. Transcriptomic profiling of the itch-signalling pathway in cutaneous sensory ganglia in atopic dogs
3. Epicutaneous house dust mite (HDM)-induced skin lesions feature early activation of Th2/Th inflammatory and pruritogenic pathways in HDM nonsensitised dogs
4. Immunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An ant-inflammatory agent-sparing approach
5. Exploring the role of filaggrin in canine atopic dermatitis: Insights from immunohistochemical and gene polymorphism studies
6. Validity of the lymphocyte proliferation test for the diagnosis of canine food allergies with delayed reactions after oral food challenge
7. Microbes and cutaneous immunology: A complex relationship at the base of inflammatory skin diseases
8. Staphylococcus aureus activates sensory neurons to induce itch and skin damage via a V8-PAR1 axis
9. Antimicrobial evaluation of Lactobacillus casei isolated from canine cutaneous microbiota against Staphylococcus pseudintermedius clinical isolates
10. Quantifying itch and its impact on sleep using artificial intelligence and radio signals
11. Insights of the “bona fide”immunoglobulin (Ig)E: Lesions from the association between serum IgE an allergy manifestation
12. An artificial intelligence driven approach to identify the immune cell landscape in blood of pruritic dogs and cats
13. A retrospective study on the use of a high-dose (4 mg/kg) of lokivetmab in 36 dogs with allergic dermatitis
14. Analysis of the immunomodulatory properties of mycobacterium cell wall fraction on cytokine production of peripheral blood mononuclear cells of healthy dogs
15. Serum thymus and activation-regulated chemokine as a therapeutic monitoring biomarker for canine atopic dermatitis
16. Information on skin cell reactions, provided by mRNA extracted from an epicutaneous tool, on a canine model of atopic dermatitis
17. Treatment of canine atopic dermatitis with modified release mycophenolate (OKV-1001): A case series
18. Prausnits–Küstner tests revealed in vivo pathogenicity of heat-labile immunoglobulin E in serum from spontaneously allergic dogs
19. Oclacitinib maleate mechanism of action in the imiquimod (IMQ)-induced dermatitis mouse model
20. The in vitro anaphylactic properties of heat-labile and heat-stable immunoglobulin (Ig)E antibodies in dog serum
21. Different incidence of anaphylactic and nonanaphylactic immunoglobulin Es in dog serum among allergens
22. Efficacy of Der f 2/Zen-1-LAMP plasmid-based immunotherapy: A proof-of-concept study in dogs with atopic dermatitis naturally sensitised to Dermatophagoides farinae
23. Ligilactobacillus animalis isolated from canine faeces inhibits the inflammatory response associatedwith atopic dermatitis via interleukin-10 overproduction by dendritic cells
24. Circulating CD4+ monocytes in a model of house dust mite-challenged laboratory beagle dogs
25. Evaluation of filaggrin expression in dogs with atopic dermatitis before and after oclacitinib administration
26. Unlocking the potential of lipidomic analysis in canine atopic dermatitis research: Insights from a pilot study
27. Minimally invasive sampling of canine skin for investigation of the transcriptome -tolerability and feasibility
28. Reactive and proactive treatment of chronic/recurrent canine allergic otitis externa with hydrocortisone aceponate
29. Suppression of immunoglobulin (Ig)E production and allergic reactions in vivo induced by caninised anti-IgE antibody CRE-DR-B
30. Indoor mycotoxin exposure effect on atopic dermatitis in companion dogs
31. Interleukin (IL)-33 immunoexpression in different clinical presentations of canine atopic dermatitis
32. The prevalence of serum allergen-specific immunoglobulin E detected with western blotting method in canine atopic dermatitis in southeast China
33. Storage stability of allergen-specific immunoglobulin E against house dust and storage mites in sera of dogs with a focus on warm temperature and exposure to sunlight
34. Global changes in pet owner sentiment toward canine pruritus treatments: A retrospective Twitter/X based study spanning two 5-year periods between 2009 and 2022
35. Comparison between the Uni-testPC multiple tip device and the Duotip-test II double tip device in skin prick tests in dogs with atopic dermatitis
36. A comprehensive “omics” approach reveals the mechanism-of- action of oclacitinib maleate in the imiquimod (IMQ)-induced dermatitis mouse model
37. Oclacitinib treatment reduces activation and pro-inflammatory cytokine production incanine T cells
38. Evaluation of oclacitinib and prednisolone combined therapy for the control of atopic dermatitis in dogs
39. Anti-inflammatory effects of oclacitinib maleate are comparable to prednisolone in a model of house dust mite-challenged laboratory beagle dogs
40. Accuracy of different concentrations of bovine, pork, chicken and soybean protein extracts for atopy patch test in dogs
41. Oclacitinib is less effective than ciclosporin for the control of otitis and/or pododermatitis associated with atopic dermatitis in dogs
42. Adequacy of a new hydrolysed protein-based diet designed for growing puppies with adverse food reactions: A case series
43. Scratch wound assay as an in vitro approach to study atopic dermatitis effects on wound healing in canine skin cells
44. Improvement of inflammatory and cutaneous barrier function by dermal exposure to cold atmospheric-pressure plasma in atopic dermatitis clinical signs